Prenetics Says Cash Flow Turned Positive in July. Its Own Definition of Cash Flow Includes Draws on a $1 Billion Facility.

by Daniel Brenner · August 18, 2026

Senior Markets Analyst, The SmallCap Signal

Prenetics Global (Nasdaq: PRE) reported second-quarter results on Tuesday, and the headline number was growth: consolidated revenue of $46.5 million, up approximately 288% year over year, with the IM8 supplement brand contributing $45.0 million of it on approximately 359% growth. The company also said July 2026 was the first month in which consolidated Adjusted Free Cash Flow was positive, and that it expects the measure to stay positive from the third quarter onward.

That cash-flow milestone is the claim worth reading twice, because the company defines the term itself. According to the August 18 release, Adjusted Free Cash Flow means net cash from operating activities plus net fundings under the General Catalyst Customer Value Fund facility. In other words, the measure adds an external financing inflow to an operating cash figure. It is not free cash flow as that phrase is ordinarily used, and the company does not present it as such.

The facility in question was announced on July 14, 2026 and is substantial. Materials filed with that announcement describe a $1.0 billion commitment from General Catalyst's Customer Value Fund that funds up to 70% of IM8's marketing spend on a monthly cohort basis. No equity is issued; the arrangement is structured as a financial liability with a capped return tied to the performance of each funded customer cohort, no fixed maturity, no financial covenants, and no recourse beyond the funded cohorts. The same materials cited a blended gross profit to customer acquisition cost ratio of 1.44x across 248,536 customers.

So the July milestone is real but conditional on a facility whose economics run through cohort performance. If cohorts underperform the assumptions, the capped return does not go away; it simply attaches to worse underlying units. Investors reading the cash-flow line should track the operating cash component separately from the funding component when the interim statements arrive.

On the revenue itself, both segments landed inside the company's own pre-announced ranges. The release notes second-quarter revenue guidance of $46 million to $48 million against the $46.5 million reported, and IM8 guidance of $44 million to $46 million against $45.0 million. Consolidated revenue came in at the low end of its range; IM8 landed near the middle of its own.

Concentration is the structural fact underneath the growth rate. Subtracting the disclosed IM8 figure from the disclosed consolidated figure leaves about $1.5 million of second-quarter revenue from everything else, which after the divestitures is principally the legacy consumer genetics business. Ninety-seven percent of the quarter came from a brand that, by chief executive Danny Yeung's own account, did not exist 20 months ago.

The July data point extends the trajectory. IM8 booked $20.9 million of revenue in July, which the company describes as a $251 million annualized run-rate; $20.9 million times twelve is $250.8 million, so the run-rate arithmetic holds. For scale, the July 14 materials put IM8's full-year 2025 revenue at $60 million, meaning a single month of 2026 was more than a third of the brand's entire prior-year revenue.

Guidance has been moving almost continuously. The company's May 14 preliminary first-quarter release raised full-year 2026 IM8 revenue guidance to $190 million to $210 million from $180 million to $200 million. The July 14 announcement lifted it again to $210 million to $220 million. Tuesday's release takes it to $220 million to $230 million. That is three increases in roughly three months.

The 2027 figure is presented as new but is not entirely. Tuesday's release describes initiating 2027 IM8 revenue guidance of $400 million or more, with nothing assumed from upcoming product launches. The July 14 materials already carried a projected 2027 IM8 revenue of $400 million or more. The August announcement formalizes a number the company had already put in front of investors five weeks earlier.

There is also a labeling wrinkle worth flagging. The release headline describes the raise as full-year 2026 IM8 revenue guidance of $220 million to $230 million. Yeung's quoted remarks describe the same range as "raising full-year total revenue guidance to $220 to $230 million." With IM8 at $45.0 million of a $46.5 million consolidated quarter, the two framings are close in practice, but they are not the same measure, and the difference matters if the legacy business stabilizes or shrinks further.

"Twenty months ago, IM8 did not exist. This quarter it carried Prenetics to a sixth consecutive record, July became the biggest month in our history, and consolidated Adjusted Free Cash Flow turned positive for the first time and we expect it to remain positive from here," Yeung, the company's chief executive and an IM8 co-founder, said in the release.

Comparability is the last caveat. Prenetics reports under IFRS, the second-quarter figures are unaudited, and prior periods have been re-presented under IFRS 5 to reflect discontinued operations following the divestment of ACT Genomics on October 1, 2025, Europa in January 2026 and Insighta on February 13, 2026. The 288% consolidated growth rate is therefore measured against a restated base that excludes businesses the company no longer owns, not against what it originally reported for the 2025 quarter.

On the balance sheet, the July 14 materials put combined cash, investments and escrow at approximately $139.7 million as of May 31, 2026, with no debt. The company authorized a $40 million buyback on March 6, 2026 and had repurchased approximately $19 million, or 968,349 Class A shares, through May 13, 2026, per the May release. That release also disclosed a first-quarter adjusted EBITDA loss of $5.6 million on $36.0 million of revenue. Tuesday's announcement leads with revenue, run-rate and the cash-flow milestone rather than a bottom-line result, so the profitability picture will not be fully legible until the interim financial statements are filed.